ABSTRACT
INTRODUCTION
Famine has been a prominent hazard to human health throughout history, and for thousands of years the link between infection and poor nutrition has been well recognised. Today this threat is as widespread as ever, and there are approximately one billion undernourished individuals worldwide (Blackburn, 2001:397-401) . In the past century, however, the pendulum has also swung in the opposite direction, and now as many if not more people are overweight or obese (Cummings & Schwartz, 2003:453-471) .
In all populations, developed and developing, rural and urban, obesity is increasing. From 1976 From to 1980 of African-American women and 25.2% of CaucasianAmerican women were reported to be overweight or obese in the United States of America (USA) (Dustan, 1990:396) (Figure 1 ). According to the third National Health and Nutrition Examination Survey (NHANESS III), more than 55% of Americans are overweight or obese and obesity has increased by 30% during the last 50 years, while most of Europe has seen a 10 -40% increase in obesity during the last ten years (Willett, Dietz & Colditz, 1999:427; Field, Coakley, Must, Spadano, Laird, Dietz, Rimm & Colditz, 2001 :1581 . In the South African Demographic and Health Survey, it was found that 56.6% of women were overweight or obese (Puoane, Steyn, Bradshaw, Laubscher, Fourie, Lambert & Mbananga, 2002 :1041 and Mollentze, Moore, Steyn, Joubert, Steyn, Oosthuizen and Weich (1995:93) found that the prevalence of obesity in Africans is as high as 54.3% among 45-54 year old South African women.
Obesity appears to have been uncommon in Western populations until the time of the Industrial Revolution, when there were increases in urbanisation and a decrease in physical activity (Walker, 1995 (Walker, :1070 . Among sub-Saharan Africans in general, a generation or so ago there was very little gain in weight or in blood pressure, with age. Even at present, in most populations, especially in the indigent masses, obesity prevalence remains very low at 1-5%. However, in South Africa and some neighbouring countries like Botswana, Namibia and Zimbabwe (Table 1) , with the rise in socio-economic status, urbanisation, and diminishing physical activity, the proportion affected has increased (Walker, Adam & Walker, 2001:368) .
In numerous countries worldwide, such have been the increases, especially in Western populations and especially in women, that according to the World Health Organization (WHO), by the year 2025, 300 million people are likely to be obese (WHO, 1998:132) .
The apparent marked excess of obesity among African women (Van Italie, 1985:983 ) is of particular interest because it parallels the marked African female excess of several obesity-related risk factors and health outcomes (Kumanyika, 1987:45) . It has been speculated that even severe obesity in African women may be far less detrimental than in Caucasian women (Walker & Segal, 1980:263; Walker, Walker, Walker & Vorster, 1989:227) . Although some research groups (Walker et al. 1989:228) have regarded obesity in African women as "healthy obesity", a South African study showed an unexpectedly high prevalence of hypertension and moderate-risk hypercholesterolemia in an African population, in which a high prevalence of obesity was also found (Mollentze et al. 1995:95) .
Obesity risks of African women may be enhanced by the presence of multiple risk factors (Kumanyika, 1987:45) . Along with obesity, elevated blood pressure and mortality due to heart disease, stroke, and diabetes occur in African women at rates that are 1.5 to 2.5 times the rates in Caucasian women. Across the board, African women are more frequently classified as overweight than Caucasian women in a ratio approaching or exceeding 2:1 (Kumanyika, 1987:32) .
Diabetes is more common in Africans than it is in Caucasians (Dustan, 1990:398) and this may explain part of the difference in the prevalence of hypertension between them. Ethnic differences in mortality, from selected diseases including diabetes are of interest. As seen from Table 2 , mortality among Africans is greater than among Caucasians for all of the listed diseases.
It would be of interest to focus on diabetes mellitus for which death rates of African women are highest of all.
This may relate to the increased prevalence of obesity among African women (Dustan, 1990:398) .
On the question of causes, no clear mechanism for the excess obesity in African women can be identified. To prevent and treat obesity, especially in African women, more should be known about the underlying causes of obesity among these women to develop ap-
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With the advent of this chronic metabolic overload, a new set of problems and complications at the intersection of metabolism and immunity has emerged, which includes the obesity-linked inflammatory diseases diabetes and atherosclerosis (Hotamisligil, 2004:953-962) .
There is now considerable evidence supporting the idea that obesity is, in fact, an inflammatory condition.
Crucial questions that are currently open regard the initiation of the inflammatory response. How and why does the body initiate an inflammatory response to obesity? Does obesity per se induce an inflammatory response, or is inflammation initiated as a secondary event by hyperlipidemia or hyperglycemia?
The aim of this review article is to point out how obesity can be described as an inflammatory condition, which may partly be the mechanism for the development of non-communicable diseases.
PATHOPHYSIOLOGY OF OBESITY
It is clear from the literature that obesity is a critical public health problem. Obesity is classified as a body mass index (BMI) of 30 kg/m² or more and it is functionally defined as the percent body fat (32%) (Lohman, 1992:80) at which disease risk increases (Figure 2 ) (Kumanyika & Adams-Campbell, 1991:48) . Obesity is an underlying factor in many diseases but the factors responsible for the causation of obesity are poorly understood. Environmental, behavioural, and genetic factors have been shown to contribute to the development of obesity (Pi-Sunyer, 2002:975) .
Genetics versus environment
The relative contributions of genetics and environment to the etiology of obesity have been evaluated in many studies. Although it varies from study to study, approximately 30%-40% of the variance in BMI can be attributed to genetics and 60%-70% to environment. The interaction between genetics and environment is also important. In a given population, some people are genetically predisposed to develop obesity, but that genotype may be expressed only under certain adverse environmental conditions, such as high-fat diets and sedentary lifestyles (Stunkard, 1988:902-23) Adapted from Kumanyika & Adams-Campbell (1991:48) . More evidence for the harmful effects of abdominal obesity became available from the Nurses' Health Study in which it was found that a higher WC was associated with an increased risk of CHD, even after controlling for BMI (Rexrode, Carey, Hennekens, Walter, Colditz, Stampfer, Willet & Manson, 1998 :1846 .
Metabolic predictors

OBESITY AND CARDIOVASCULAR DIS-EASE
Obesity places a heavy burden on the entire cardiovascular system, contributing to considerable overall morbidity and mortality ( Figure 2 ).
Obesity has adverse effects on several coronary artery disease (CAD) risk factors. Obese patients are more likely to be hypertensive than lean patients, and weight gain is typically associated with increases in arterial pressure (Lavie & Messerli, 1986:275-279) , and independent of arterial pressure, obesity increases the risk of left ventricular hypertrophy (LVH) (Lavie, Venture & Messerli, 1992:134-143) . Obesity also adversely affects plasma lipids, especially increasing triglycerides and decreasing the cardio protective levels of high-density lipoprotein cholesterol, and is the major contributor to adult-onset diabetes mellitus and the insulin resistance syndrome, which are associated with high levels of inflammation and overall cardiovascular mortality (Lavie & Milani, 1997:397-401) . Despite adversely affecting these risk factors, including markedly increasing levels of high sensitivity CRP (Lavie, Milani & Morshedi, 2003:177A-178A) , data from the Framingham Heart
Study have indicated that obesity is an independent risk factor for major CAD events in men and, particularly, in women (Hubert, Feinleib, McNamara & Castelli, 1983:968-977) .
Obesity has been hypothesised to induce LVH by various mechanisms. One important mechanism may be related to the increased circulatory blood volume of obesity. As a consequence, cardiac output increases because of an increase in stroke volume. The increases in circulating blood volume and cardiac output produces an increase in left ventricular cavity size, which produces an increase in left ventricular wall stress in accordance with Laplace's law (Abate, 1999:12) .
In addition to increasing eccentric LVH and the propen- 
ADIPOSE TISSUE AND INFLAMMATORY MARKERS
The adipocyte is another important component of inflammation. Until relatively recently adipose tissue was considered a passive storage depot for fat but is now known to play an active role as an endocrine organ in metabolism (Flier, 1995:15) . This remarkable understanding is allowing us to more clearly define the role adipocytes play in health and in obesity and how in- production (Heinrich, Castell & Andus, 1990:621-636; Van Snick, 1990:253-278) , thereby contributing to the maintenance of a chronic low-grade inflammation state involved in the progression of obesity and its associ- 
Interleukin-6
The reason for increased production of CRP in obesity is most likely due to the action of IL-6. IL-6 is a cytokine and CRP, which could partially account for increased mortality rates in abdominally obese subjects if IL-6 or CRP contributed to disease promotion (Heilbronn & Clifton, 2002:317) .
Although little is known about the effects of IL-6 on adipose tissue, one possible action is a down-regulation of adipose tissue lipoprotein lipase (Greenberg, Nordan, McIntosh, Calvo, Scow & Jablons, 1992:4115) .
The regulated production of this multifunctional cytokine may modulate regional adipose tissue metabolism and may contribute to the recently reported correlation between serum IL-6 and the level of obesity (Fried et al. 1998:850) .
C-reactive protein
C-reactive protein (CRP) is an acute phase reactant, synthesised primarily in hepatocytes and secreted by the liver. It is regulated by a variety of inflammatory cytokines of which interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-á) are mainly involved (Heilbronn & Clifton, 2002:316-319 ).
CRP has a normal range of < 2 mg/l in populations without evidence of acute illness (Gabay & Kushner, 1999:452) . Therefore, enhanced levels of CRP can be used as a sensitive marker of systemic inflammation (Das, 2001:954 (Rohde, Hennekens & Ridker, 1999 :1021 .
Concerning the relationship between CRP concentration and BMI level, it was found that the prevalence of elevated CRP levels (concentrations = 22 mg/l) is higher in both overweight (BMI 25-29.9 kg/m²) and obese (BMI = 30 kg/m²) patients than in normal weight (BMI < 25 kg/m) subjects (Visser, Bouter, McQuillan, Wener & Harris, 1999 :2133 . Even moderately elevated CRP plasma concentrations have been associated with a significant increase in risk of future myocardial infarction, stroke and peripheral atherosclerosis among apparently healthy middle-aged men and women (Ridker, Cushman, Stampfer, Tracy & Hennekens, 1998:427; Ridker, Buring, Shih, Matias & Hennekens, 1998:732) even after adjustment for known cardiovascular risk fac- Pannacciulli et al. (2001 Pannacciulli et al. ( :1419 hypothesised that adipose tissue is responsible for a mild, chronic inflammatory state, as expressed by levels of CRP, ILtors (Rohde et al. 1999 (Rohde et al. :1021 .
Adipose tissue
In particular, CRP concentrations have been recently demonstrated to be as strong as apolipoprotein B-100 levels and TC/HDL-C ratio in predicting the risk of cardiovascular events in women and even stronger than concentrations of TC, HDL-C, lipoprotein(a) and homocysteine (Ridker, Hennekens, Buring & Rifai, 2000:842) . This may explain the increased risk of diabetes, heart disease and many other chronic diseases in the obese.
In a study by Rexrode et al. (2003:7) , BMI was the strongest predictor of elevated inflammatory markers (Figure 3 ). The associations with BMI were dramatic; women in the highest BMI quartile (BMI = 28.3 kg/m²) had a more than twelve-fold increased risk of having elevated CRP levels and a more than four-fold increased risk of elevated IL-6 levels and higher CRP and IL-6 levels were observed with each increment in BMI (Figure 4 ). 
Assays of inflammatory markers
Both TNF-á and IL-6 are measured by enzyme-linked immunosorbent assay (ELISA) for in vitro quantitative determination of TNF-á and IL-6, respectively, in human serum, plasma or buffered solutions of cell culture medium (Diaclone, Gleming, France). Monoclonal antibodies specific for TNF-á or IL-6 is used in these assays. CRP is measured by a high sensitivity test 
ATHEROSCLEROSIS AS AN INFLAM-MATORY DISEASE
Elevated lipid levels are characteristic of obesity, infection and other inflammatory states. Hyperlipidemia in obesity is responsible in part for inducing peripheral tissue insulin resistance and dyslipidemia and contributes to the development of atherosclerosis (Wellen & Hotamisligil, 2005 :1112 . It is interesting to note that metabolic changes characteristic of the acutephase response are also proatherogenic; thus, altered lipid metabolism that is beneficial in the short term in fighting against infection is harmful if maintained chronically (Khovidhunkit et al. 2004 (Khovidhunkit et al. :1169 (Khovidhunkit et al. -1196 .
Atherosclerosis is accelerated both directly by effects of cytokines on endothelial cells and indirectly by cytokine effects on the liver, causing increased production of CRP and related factors (Libby & Ridker, 1999 :148-1150 . The chronic inflammatory process involving the arterial endothelium that ultimately results in the complications of atherosclerosis may be caused by a response to the oxidative components of modified low-density lipoprotein (LDL), chronic infection or even free radicals (Paoletti, Gotto & Hajjar, 2004:III-20) .
Atherosclerosis is a multi-factorial, multi-step disease that involves chronic inflammation at every stage, from initiation to progression and, eventually, plaque rupture (Libby, Ridker & Maseri, 2002 :1135 -1143 .
In atherosclerosis, the normal homeostatic functions of the endothelium are altered, promoting an inflammatory response (Prescott, McIntyre, Zimmerman & Stafforini, 2002:727-33) . The association of inflammation with the initiation and progression of atherosclerosis suggest that markers of inflammation like CRP may be useful in predicting an increased risk of coronary heart disease.
In a review by Lind (2003:208) , the idea that circulating biomarkers of inflammation are associated with atherosclerotic diseases as well as with acute coronary syndromes, indicative of plaque rupture, is supported.
It is, however, a question whether or not these markers of inflammation really are markers or if they are actively involved in the atherosclerotic process. CRP has been detected in early human atherosclerotic plaques (Torzewski, Torzewski, Bowyer, Frohlich, Koenig, Waltenberger, Fitzsimmons & Hombach, 1998 :1386 , and its appearance in plaques has been related to the intima-media thickness of the carotid arteries (Zhang, Cliff, Shoefl & Higgins, 1999:375-9) . It has been shown that IL-6 gene transcripts are expressed in human atherosclerotic lesions (Rus, Vlaicu & Niculescu, 1996:263-71) , and it has also been shown that endothelial expression of adhesion molecules occurs in human atherosclerotic plaques and is an early manifestation of experimental cholesterol-induced atherosclerosis (Davies, Gordon, Gearing, Pigott, Woolf, Katz, & Kyriakopoulos, 1993:223-9) . Thus, it appears as if there is some evidences that some of these markers of inflammation could be directly involved in the formation and progression of atherosclerosis, although more definitive proofs yet have to be presented.
INFLAMMATION AND DIABETES
Type II diabetes is a leading cause of morbidity and mortality. Prevention of diabetes and its associated burden, primarily cardiovascular morbidity and mortality, have become major health issues worldwide (Venkat, Gregg, Fagot-Campagna, Engelgau & Vinicor, 2000:S77-S84) . Although type II diabetes was characterised as a disease associated with insulin resistance even before insulin could be measured in the blood, the central importance of insulin resistance was not fully recognised until the early 1980's (Bergman, Finegood & Ader, 1985:45-86) . Numerous studies documented the inverse relationship between body mass index and insulin sensitivity suggesting that obesity is a cause of insulin resistance. While increasing body fat was associated with decreasing insulin sensitivity, the muscle mass was thought to be central to insulin resistance given its relative size and significant contribution to glucose utilisation. That signalling molecules secreted by adipose tissue played a major role in this insulin resistance was first appreciated in the mid-1990s with the discovery of leptin (Finegood, 2003:S4) . That other secretory products of the adipocyte, including the inflammatory cytokine TNF-á, might control insulin sensitivity was suggested by the work of Hotamisligil, Shargill and Speigelmann (1993:87-91) .
In a report by Duncan, Schmidt, Pankow, Ballantyne, Couper, Vigo, Hoogeveen, Folsom and Heiss (2003:1802) 
THERAPEUTIC IMPLICATIONS OF THE EFFECTS OF DRUGS AND EXERCISE
The association of inflammatory markers with increased risk for CHD suggest the use of anti-inflammatory treatment to reduce the risk for future CHD events. However, no prospectively designed studies have so far assessed clinical benefits after specific treatment of these markers. Such studies would indicate whether inflammatory markers could be used not only in risk stratification but also to determine therapeutic efficacy.
The effects of statins on CRP
In several trials, the effects of statins on CRP levels appeared unrelated to their effects on lipid levels, suggesting that statins may exert an anti-inflammatory action (Ridker, Rifai, Pfeffer, Sacks, Moye, Goldman, Flaker & Braunwald, 1998:839-44; Ridker, Rifai, Clearfield, Downs, Weis, Miles, Gotto & Phil, 2001 :1959 -1965 In the CARE study, it was shown that a statin given for five years reduced CRP-levels compared with placebo (Ridker, Rifai, Pfeffer, Sacks & Braunwald, 1999:230-5 ) and circulating levels of IL-6 and TNF-á have also been shown to be reduced by treatment with statins (Rosenson, Tangney & Casey, 1999:983-4) .
Angiotensin-Converting Enzyme Inhibition
By interrupting the expression of adhesion molecules and cytokines, angiotensin-converting enzyme (ACE) inhibitors exert anti-inflammatory effects on the development of atherosclerosis and on the plaque rupture that initiates acute coronary syndromes (Halkin & Keren, 2002:126-34) . In the future, identification of specific markers of inflammation may identify a subpopulation of high-risk post-MI patients and others for whom therapy with an ACE inhibitor will be more effective than it is for the total patient population.
Aspirin or Acetylic-salicylic acid (ASA)
ASA treatment is one of the most established treatments for atherosclerotic complications. Aspirin has anti-platelet and anti-inflammatory activities. The ability of aspirin to decrease the incidence of a first thrombotic event, including myocardial infarction (MI), ischemic stroke, and venous thrombosis, was measured with respect to CRP levels. Men with the highest CRP levels had an increased risk for MI among men in the highest quartile of CRP levels, but not among those in the lowest quartile. This result suggests that the relation of CRPmediated inflammation to vascular risk is confined to the arterial circulation, that aspirin acts as an antiinflammatory agent, and that CRP levels may identify persons who are more likely to respond to aspirin therapy (Ridker, Cushman, Stampfer, Tracy & Hennekens, 1997:973-79) . Both levels of CRP and IL-6 have been shown to be reduced during ASA-treatment in patients with CAD (Ikonomidis, Andreotti, Economou, Stefanadis, Toutouzas & Nihoyannopoulos, 1999:793-98) .
Weight loss and physical activity Lemieux et al. (2001:966) It is suggested by Saito, Ishimitsu, Minami, Ono, Ohrui and Matsuoka (2003:78) that correction of overweight may be effective in reducing plasma CRP. Indeed, in a recent study, Tchernof, Molan, Sites, Ades and Poehlman (2002:567) reported that adiposity was a significant predictor of plasma CRP and that caloric restriction-induced weight loss markedly reduced plasma CRP in obese postmenopausal women. It has also been reported by Smith, Dykes, Douglas, Krishnaswamy and Berk (1999:1725) that moderate exercise reduces inflammation markers. In their study, they reported CRP levels as measured before an exercise programme which ranged from 0 to 0.9 mg/dL in the lower quartile to 5.8 to 37.5 mg/dL in the upper quartile, with a mean value of 4.81 (1.09) mg/dL. Va-lues taken after the exercise programme decreased by 35% to 3.13 (0.64) mg/dL (P = 0.12) (2-sided t-test).
The frequency of values in the upper quartile dropped by 50% after following the exercise programme (P= 0.01). Tisi, Hulse, Chulakadabba, Gosling and Shearman (1997:347) evaluated several markers of disease severity in a randomised trial of therapeutic exercise training in 49 patients with intermittent claudication. In their findings, serum CRP levels were significantly reduced after 3 to 6 months of regular physical activity. The observation by Rohde et al. (1999 Rohde et al. ( :1021 that men who exercise regularly were more likely to have lower CRP levels is consistent with the findings of Tisi et al. (1997:347) , as well as with the known beneficial effects of regular physical activity. Abramson and Vaccarino (2002 :1288 -1289 ) also found that more frequent physical activity is independently associated with lower odds of having elevated inflammation levels among apparently healthy US adults 40 years and older, independent of several confounding factors. They found that among those engaging in low, medium and high physical activity levels, the percentages of persons with elevated CRP levels were More and more reports are indicating that markers of inflammation are predictive of increased CHD incidence and mortality, (Rohde et al. 1999 (Rohde et al. :1021 Danesh, Whincup & Walker, 2000:199-204 ) and the development of CHD is increasingly being viewed as an inflammatory process (Ridker et al. 1998:733) . As such, it might be reasonable to hypothesise that if physical activity lowers CHD risk, it may do so in part by preventing or reducing inflammation. It is not clear how physical acAs reported by Abramson and Vaccarino (2002:1289) . 15.1%, 9.7%, and 6.5% respectively. As physical activity levels increased, the odds of having an elevated CRP level significantly decreased independent of other factors ( Figure 5 ).
In another study, Ford (2002:567) found that physical activity is inversely associated with CRP concentrations, suggesting that physical activity may mitigate inflammation. These results add to mounting evidence that physical activity may reduce inflammation, which is a critical process in the pathogenesis of cardiovascular disease. Taken together, these physical and dietary approaches to correct obesity may be promising in inhibiting cardiovascular inflammation and future risk of developing cardiovascular diseases (Saito et al. 2003:78) .
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HEALTH (Pyne, 1994:55) . In contrast, however, there are plausible mechanisms by which physical activity could also reduce inflammation. For example, obesity is a factor that is strongly related to higher levels of inflammation (Visser et al. 1999 (Visser et al. :2135 and it has been suggested that physical activity may reduce inflammation by reducing obesity levels (Geffken et al. 2001:248) . However, in the study done by Abramson and Vaccarino (2002:1289) , it was observed that physical activity was associated with lower levels of inflammation even after adjustment for measures of general obesity (BMI) and central obesity (WHR). Therefore, they found it unlikely that the association between activity and inflammation is mediated entirely by reductions in obesity.
Since elevated levels of CRP and other markers of inflammation have been shown to be important predictors of increased CHD risk (Ridker et al. 1998:733) 
SUMMARY
The etiology of obesity represents a complex interaction of genetics, diet, metabolism and physical activity levels. Obesity has been positively associated with increased serum concentrations of vascular inflammatory markers, and adipose tissue has been proposed as a factor directly modulating pro-inflammatory cytokine levels. Individuals with obesity are also at an increased risk for various chronic diseases like diabetes and atherosclerosis which are also characterised by elevated CRP concentrations. Elevated CRP levels have also been independently associated with increased risk of myocardial infarction, ischemic heart disease and peripheral arterial disease. This is interesting because more frequent physical activity is associated with lower odds of having elevated inflammation levels. Research suggests that the antiinflammatory effects of regular physical activity may mediate the association between physical activity and reduced coronary heart disease risk.
From the preceding discussion it is evident that low- 
